Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Swine Flu Variation Emerges With Power to Resist Drug Treatment

Don't Miss Out —
Follow us on:

June 9 (Bloomberg) -- A novel form of the swine flu virus that swept the globe in 2009 has emerged in Australia and Singapore, carrying a genetic twist that helps it resist Roche Holding AG’s Tamiflu and GlaxoSmithKline Plc’s Relenza, researchers said.

More than 10 percent of the infections in Singapore and 30 percent of those in northern Australia tested in early 2011 had mildly reduced sensitivity to the two drugs that are the mainstay of influenza treatment, according to a report today from the World Health Organization’s influenza research group in North Melbourne, Australia. BioCryst Pharmaceuticals Inc.’s experimental flu drug peramivir remained an effective treatment against the virus in laboratory tests, the researchers said.

The new variation of H1N1 mixed with an older form of the virus in at least one patient, the researchers said. The infection was extremely resistant to Tamiflu and the individual, who had a weakened immune system, died of multiple organ failure. With other flu strains circulating in the U.K. and elsewhere, there is a risk of future combinations of drug-resistant virus, they said.

The new variation appears to spread easily among people, according to the report in the journal Eurosurveillance. If it circulates widely, researchers said they are concerned that other mutations may occur and trigger even greater drug resistance and more serious illness.

Influenza is a rapidly evolving virus, and the severity of the season depends on which strains are circulating and how well a population has been inoculated. Annual deaths in the U.S. associated with seasonal flu ranged from 3,349 to 48,614 from 1976 to 2007, according to the Centers for Disease Control and Prevention. About 90 percent of flu-related deaths are in people ages 65 or older.

The H1N1 virus was reported in more than 214 countries and caused about 18,450 deaths worldwide through August when the World Health Organization declared an end to the pandemic.

To contact the reporter on this story: Michelle Fay Cortez in Minneapolis at mcortez@bloomberg.net

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.